Get the Stockscreener App
7.21
3.87%
-0.29
After Hours:
7.14
-0.07
-0.97%
Edesa Biotech Inc stock is traded at $7.21, with a volume of 65,444.
It is down -3.87% in the last 24 hours and up +32.05% over the past month.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.
See More
Previous Close:
$7.50
Open:
$7.43
24h Volume:
65,444
Relative Volume:
0.13
Market Cap:
$69.41M
Revenue:
-
Net Income/Loss:
$-7.82M
P/E Ratio:
-6.2887
EPS:
-1.1465
Net Cash Flow:
$-8.00M
1W Performance:
-6.00%
1M Performance:
+32.05%
6M Performance:
+383.89%
1Y Performance:
+246.63%
1-Day Range:
$7.04
$7.63
1-Week Range:
$7.04
$8.89
52-Week Range:
$0.72
$20.32
Edesa Biotech Inc Stock (EDSA) Company Profile
Name
Edesa Biotech Inc
Sector
Industry
Phone
(905) 475-1234
Address
100 SPY COURT, MARKHAM, ON
Compare EDSA vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EDSA
Edesa Biotech Inc
|
7.21 | 78.27M | 0 | -7.82M | -8.00M | -1.1465 |
VRTX
Vertex Pharmaceuticals Inc
|
529.59 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
649.81 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
916.80 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
313.04 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.99 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Edesa Biotech Inc Stock (EDSA) Latest News
Why Did EDSA Stock Rally More Than 70% Today? - Stocktwits
Brookline Capital Initiates Edesa Biotech(EDSA.US) With Buy Rating, Announces Target Price $21 - Moomoo
Brookline initiates Edesa Biotech stock with buy on pipeline - Investing.com
Edesa Biotech Inc (EDSA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Edesa Biotech, Inc. Actuals & Estimates (NASDAQ:EDSA) - TradingView
EDSA Should I Buy - Intellectia AI
Price to book forward of Edesa Biotech, Inc. – NASDAQ:EDSA - TradingView
EDSA Forecast — Price Target — Prediction for 2027 - TradingView
Edesa Biotech Inc (EDSA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Edesa Biotech Inc (EDSA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Edesa Biotech Inc (EDSA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
EDSA Stock Rallied Over 50% Today: What’s Ahead For The Small-Cap Biotech? - Stocktwits
CEO, Company Secretary & Director of Edesa Biotech Pardeep Nijhawan Buys 28% More Shares - simplywall.st
Edesa Biotech (EDSA) joint filing reports 5.4% stake by Millennium group - Stock Titan
Edesa Biotech announces $3.5M PIPE financing - MSN
Edesa Biotech Inc (EDSA) Institutional Confidence - TradingKey
Edesa Biotech Inc (EDSA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Edesa Biotech Inc (EDSA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Edesa Biotech Inc (EDSA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Edesa Biotech Inc (EDSA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Nijhawan lifts Edesa Biotech (EDSA) beneficial ownership stake to 19.99% - Stock Titan
Edesa Biotech (EDSA) CEO invests $799,995.50 in private share purchase - Stock Titan
Edesa Biotech Inc. Q1 2026 Earnings: Wider-than-Expected Loss as Pre-Commercial R&D Costs PersistMargin Compression Risk - newsline.com
Edesa Biotech Advances on Promising Drug Trial Results - timothysykes.com
Edesa Biotech Gains Ground with Positive Clinical and Financial News - timothysykes.com
EDSA Q1 2026 Earnings: Misses EPS Estimates Amid Pre-Revenue Stage, Stock Rises 2.65%Mid-Term Outlook - newsline.com
Edesa Biotech Surpasses Expectations with Promising Phase 3 Data - timothysykes.com
Edesa Biotech Inc. (EDSA) Posts Strong 8.45% Gain, Testing Key ResistanceValue Factor - newsline.com
Edesa Biotech secures $3.5 million private placement financing By Investing.com - Investing.com Australia
Edesa Biotech announces $3.5M private placement - TipRanks
Edesa Biotech Announces Insider-Led PIPE Financing Agreement - TipRanks
Edesa Biotech secures $3.5 million private placement financing - Investing.com
Edesa Biotech Raises $3.5 Million in Private Placement, Issues 729,241 Shares - TradingView
Edesa Biotech (Nasdaq: EDSA) sets $3.5M PIPE led by CEO - Stock Titan
Edesa Biotech, Inc. Announces $3.5 Million PIPE Financing to Advance Clinical Programs - Quiver Quantitative
Edesa Biotech Announces $3.5 Million Private Placement of - GlobeNewswire
Edesa Biotech, Inc. announced that it expects to receive $3.42014 million in funding - marketscreener.com
Edesa Biotech Company Profile & Introduction - Moomoo
Edesa Biotech Q1 2026 Earnings: EPS Miss Widens Loss, Shares Fall 23%One-Time Gain Impact - newsline.com
Edesa reports exploratory data on AKI treatment candidate - Investing.com UK
Edesa reports exploratory data on AKI treatment candidate By Investing.com - Investing.com South Africa
Edesa Biotech Says Paridiprubart Linked to Lower Risk of Death in Acute Kidney Injury Patients - marketscreener.com
Edesa Biotech Inc Stock (EDSA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Edesa Biotech Inc Stock (EDSA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Nijhawan Pardeep | Chief Executive Officer |
Mar 10 '26 |
Buy |
6.60 |
1,000 |
6,599 |
628,813 |
| Nijhawan Pardeep | Chief Executive Officer |
Mar 05 '26 |
Buy |
3.90 |
10,000 |
39,000 |
402,702 |
| Nijhawan Pardeep | Chief Executive Officer |
Mar 04 '26 |
Buy |
4.26 |
10,000 |
42,560 |
392,702 |
| Nijhawan Pardeep | Chief Executive Officer |
Mar 03 '26 |
Buy |
3.63 |
10,000 |
36,300 |
382,702 |
| Nijhawan Pardeep | Chief Executive Officer |
Mar 02 '26 |
Buy |
2.00 |
2,000 |
4,000 |
627,813 |
| Nijhawan Pardeep | Chief Executive Officer |
Mar 02 '26 |
Buy |
2.28 |
1,000 |
2,280 |
372,702 |
| Nijhawan Pardeep | Chief Executive Officer |
Feb 27 '26 |
Buy |
2.22 |
30,000 |
66,696 |
371,702 |
| Nijhawan Pardeep | Chief Executive Officer |
Feb 26 '26 |
Buy |
1.58 |
20,571 |
32,480 |
615,797 |
0.05%
0.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):